FCGR3A and neoplasm: Treatment with α-EGFR/α-CD16/α-4-1BB NPs had the most robust treatment responses with tumor growth delays averaging 24 days after initial treatment and prolonged survival averaging 18 days compared to the nontreatment group (P=0.0018).